NCT04332744 - Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer (ZZ-First) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

May 6, 2025

Study Completion Date

May 6, 2025

Conditions

Metastatic Prostate Cancer

Interventions

DRUG

Enzalutamide

Enzalutamide capsules orally once daily and continuously (160 mg) in 28-day cycles (every four weeks)

DRUG

Talazoparib

Talazoparib capsules orally once daily and continuously (0.5 mg) in 28-day cycles (every four weeks)

Trial Locations (8)

Institut Català d'Oncologia Badalona, Badalona

Hospital Clínic i Provicial de Barcelona, Barcelona

Hospital del Mar, Barcelona

Hospital Vall d'Hebrón, Barcelona

Hospital Universitario 12 de Octubre, Madrid

Hospital Universitario Virgen de la Victoria, Málaga

Instituto Valenciano de Oncología (IVO), Valencia

Hospital Universitario Miguel Sevet, Zaragoza